Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
600420 Shanghai Shyndec Pharmaceutical
- 10.85
- +0.25+2.36%
Not Open Apr 1 15:00 CST
14.55BMarket Cap13.43P/E (TTM)
10.99High10.62Low303.31KlotVolume10.62Open10.60Pre Close329.68MTurnover2.26%Turnover Ratio13.43P/E (Static)1.34BShares14.4152wk High1.10P/B14.55BFloat Cap8.3352wk Low11.66Limit Up1.34BShs Float29.32Historical High9.54Limit Down3.49%Amplitude0.07Historical Low0.20Dividend TTM10.87Avg Price128.60KlotAsk1.84%Div YieldTTM100Lot Size173.57KlotBid
Shanghai Shyndec Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -9.38%10.94B | -6.21%8.59B | -7.52%5.96B | -8.60%3.12B | -6.86%12.07B | -5.73%9.16B | 0.90%6.44B | 5.33%3.42B | -7.07%12.96B | -9.25%9.72B |
| Operating revenue | -9.38%10.94B | -6.21%8.59B | -7.52%5.96B | -8.60%3.12B | -6.86%12.07B | -5.73%9.16B | 0.90%6.44B | 5.33%3.42B | -7.07%12.96B | -9.25%9.72B |
| Other operating revenue | -40.71%167.77M | ---- | -49.79%87.58M | ---- | 88.93%282.98M | ---- | 163.15%174.44M | ---- | -20.77%149.79M | ---- |
| Total operating cost | -16.28%9.21B | -13.29%7.15B | -14.87%4.94B | -14.65%2.63B | -8.67%11B | -8.52%8.25B | -2.67%5.8B | 1.15%3.08B | -6.64%12.04B | -8.30%9.01B |
| Operating cost | -10.73%6.65B | -7.45%5.18B | -8.22%3.6B | -9.00%1.85B | -7.23%7.44B | -4.36%5.6B | 3.33%3.92B | 9.21%2.03B | 2.25%8.02B | -1.97%5.86B |
| Operating tax surcharges | -4.76%131.55M | -3.97%91.85M | 3.48%67.55M | 32.16%38.4M | 20.82%138.12M | 18.67%95.65M | 19.85%65.28M | 3.45%29.06M | -11.67%114.32M | -16.54%80.6M |
| Operating expense | -46.51%1.15B | -42.03%969.12M | -42.79%716.48M | -36.65%453.6M | -21.59%2.15B | -23.66%1.67B | -16.12%1.25B | -13.14%715.99M | -21.19%2.75B | -20.65%2.19B |
| Administration expense | 3.01%793.27M | 0.71%556.79M | 3.83%373.76M | 7.40%184.15M | 12.59%770.07M | -7.27%552.88M | -11.18%359.97M | -8.04%171.46M | -8.72%683.97M | 8.94%596.23M |
| Financial expense | -17.47%-88.68M | -29.92%-67.19M | -54.55%-61.56M | -222.74%-21.07M | -63.65%-75.49M | 24.61%-51.72M | -56.72%-39.83M | -31.24%17.17M | -146.12%-46.13M | -203.53%-68.6M |
| -Interest expense (Financial expense) | -36.27%36.89M | -42.08%27.84M | -50.47%18.7M | -46.32%9.47M | -46.06%57.88M | -43.15%48.06M | -36.80%37.75M | -41.54%17.65M | -2.86%107.31M | -0.62%84.54M |
| -Interest Income (Financial expense) | 20.23%-86.97M | -0.78%-74.17M | -10.83%-54.38M | -37.78%-22.84M | -83.71%-109.02M | -81.23%-73.6M | -98.16%-49.07M | -47.38%-16.58M | -21.51%-59.35M | -22.57%-40.61M |
| Research and development | 1.14%575.93M | 10.43%416.21M | 0.42%244.6M | 9.92%121.61M | 9.31%569.43M | 4.67%376.89M | 1.69%243.58M | -5.44%110.63M | -11.59%520.92M | -6.77%360.09M |
| Credit Impairment Loss | -86.95%2.36M | -11.58%-4.01M | 78.28%-3.6M | 78.39%-2.76M | 2.64%18.05M | -175.11%-3.59M | 1.47%-16.57M | 46.18%-12.75M | 170.73%17.59M | 116.03%4.78M |
| Asset Impairment Loss | -113.01%-168.5M | -83.11%-93.83M | 60.03%-11.31M | 76.34%-3.25M | -69.38%-79.11M | -8.26%-51.24M | -33.71%-28.3M | -123.57%-13.74M | 73.43%-46.7M | -205.31%-47.34M |
| Other net revenue | 107.91%23.64M | 792.80%24.6M | 298.15%75.47M | 257.16%27.75M | -77.62%11.37M | -122.52%-3.55M | -2,157.63%-38.09M | 6.18%-17.66M | 134.67%50.8M | 188.70%15.77M |
| Fair value change income | ---- | ---- | ---- | ---- | ---- | ---- | ---3.85M | ---- | ---- | ---- |
| Invest income | 133.51%64.11M | 170.87%36.5M | 310.22%16.84M | 269.21%2.48M | 1,071.97%27.45M | 432.67%13.47M | -1,012.23%-8.01M | 69.07%-1.47M | 109.74%2.34M | 74.52%-4.05M |
| -Including: Investment income associates | 145.38%13.75M | 197.21%5.98M | 199.66%5.26M | 3.98%-1.14M | 13.24%5.6M | -88.44%-6.15M | -539.38%-5.28M | 75.47%-1.19M | 146.51%4.95M | 72.18%-3.26M |
| Asset deal income | 1.68%-31.31M | -356.62%-5.49M | -104.08%-2.05M | -2,260.59%-2.2M | -2,785.98%-31.85M | -252.57%-1.2M | -515.62%-1M | -107.35%-93.09K | -644.14%-1.1M | 268.09%788.53K |
| Other revenue | 104.38%156.99M | 134.36%91.44M | 284.81%75.59M | 221.94%33.47M | -2.37%76.81M | -36.64%39.02M | -51.75%19.64M | -28.26%10.4M | 0.91%78.68M | 42.40%61.58M |
| Operating profit | 61.97%1.75B | 60.80%1.47B | 81.30%1.1B | 62.77%524.6M | 11.95%1.08B | 26.55%913.15M | 41.28%604.93M | 75.97%322.29M | 7.64%966.14M | -16.40%721.57M |
| Add:Non operating Income | -40.14%15.26M | -54.45%10.04M | -57.34%7.75M | -72.33%802.85K | -41.53%25.49M | -44.74%22.05M | 110.08%18.17M | -28.44%2.9M | -7.76%43.59M | -22.34%39.9M |
| Less:Non operating expense | 791.53%94.13M | 126.68%21.72M | 226.24%18.05M | 2,501.30%17.4M | -58.77%10.56M | -46.17%9.58M | -53.01%5.53M | -87.92%668.89K | -3.78%25.61M | -0.91%17.8M |
| Total profit | 52.57%1.67B | 57.38%1.46B | 75.92%1.09B | 56.54%508M | 11.43%1.1B | 24.47%925.61M | 45.30%617.56M | 78.64%324.53M | 7.18%984.12M | -17.05%743.66M |
| Less:Income tax cost | 158.41%340.97M | 100.80%257.24M | 93.63%199.51M | 63.42%82.15M | 13.13%131.95M | -8.16%128.11M | 8.44%103.04M | 10.26%50.27M | 20.16%116.63M | 44.02%139.49M |
| Net profit | 38.10%1.33B | 50.40%1.2B | 72.37%886.89M | 55.27%425.86M | 11.20%964.61M | 32.00%797.5M | 55.91%514.52M | 101.54%274.26M | 5.64%867.48M | -24.45%604.17M |
| Net profit from continuing operation | 38.10%1.33B | 50.40%1.2B | 72.37%886.89M | 55.27%425.86M | 11.20%964.61M | 32.00%797.5M | 55.91%514.52M | 101.54%274.26M | 5.64%867.48M | -24.45%604.17M |
| Less:Minority Profit | -8.90%248.46M | 4.85%244.92M | -0.69%168.41M | -0.46%94.6M | 13.78%272.73M | 31.37%233.58M | 61.25%169.58M | 62.60%95.04M | -5.21%239.69M | 5.68%177.8M |
| Net profit of parent company owners | 56.62%1.08B | 69.27%954.53M | 108.29%718.48M | 84.83%331.26M | 10.21%691.88M | 32.26%563.92M | 53.41%344.94M | 130.87%179.22M | 10.47%627.79M | -32.48%426.37M |
| Earning per share | ||||||||||
| Basic earning per share | 48.72%0.808 | 57.87%0.7117 | 87.31%0.5357 | 61.54%0.247 | -11.12%0.5433 | 8.57%0.4508 | 30.65%0.286 | 102.25%0.1529 | 10.46%0.6113 | -32.48%0.4152 |
| Diluted earning per share | 48.72%0.808 | 57.87%0.7117 | 87.31%0.5357 | 79.51%0.247 | 0.07%0.5433 | 21.94%0.4508 | 45.55%0.286 | 99.71%0.1376 | 12.52%0.5429 | -30.90%0.3697 |
| Other composite income | 92.56%174.84K | -50.74%-111.67K | -51.39%-111.67K | -81.75%90.8K | -109.10%-74.08K | -218.27%-73.77K | -108.42%-33.46K | 96.61%497.48K | 21.42%814.02K | |
| Other composite income of parent company owners | 92.56%174.84K | -50.74%-111.67K | -51.39%-111.67K | ---- | -81.75%90.8K | -109.10%-74.08K | -218.27%-73.77K | -108.42%-33.46K | 96.61%497.48K | 21.42%814.02K |
| Total composite income | 38.10%1.33B | 50.40%1.2B | 72.37%886.78M | 55.29%425.86M | 11.14%964.7M | 31.81%797.43M | 55.90%514.45M | 100.93%274.23M | 5.67%867.98M | -24.41%604.99M |
| Total composite income of parent company owners | 56.62%1.08B | 69.27%954.41M | 108.30%718.37M | 84.86%331.26M | 10.14%691.97M | 31.99%563.85M | 53.39%344.87M | 129.65%179.19M | 10.51%628.29M | -32.42%427.19M |
| Total composite income of minority owners | -8.90%248.46M | 4.85%244.92M | -0.69%168.41M | -0.46%94.6M | 13.78%272.73M | 31.37%233.58M | 61.25%169.58M | 62.60%95.04M | -5.21%239.69M | 5.68%177.8M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.